News

William Blair Remains Bullish on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the top most undervalued biotech stocks to buy now. On August 7, William Blair analyst ...
TipRanks on MSN3d

Genmab Announces Capital Increase Following Employee Warrant Exercise

Genmab ( ($GMAB) ) has issued an update. On August 12, 2025, Genmab A/S announced a capital increase of 4,563 shares following the exercise of ...
TipRanks on MSN16h

Genmab price target raised to $36 from $35 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

European shares near two-week highs on Fed rate cut expectations

European shares hit a near two-week high on Wednesday, underpinned by gains in heavyweight healthcare and technology stocks, ...
PharmaTimes2d

Genmab’s epcoritamab combination meets key endpoints in phase 3 lymphoma trial

Genmab has announced that its phase 3 EPCORE FL-1 trial met both primary endpoints in patients with relapsed or refractory ...

10 Most Undervalued Biotech Stocks to Buy Now

In this article, we will look at the 10 Most Undervalued Biotech Stocks to Buy Now. On July 25, Salveen Richter, Goldman Sachs’ lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the ...